Apyx Medical Corp. reported total revenue of $13.9 million for the second quarter, a 22% increase from $11.4 million a year prior. The company’s EPS of $-0.07 surpassed the consensus estimate of $-0.08, signifying a slight resilience and potential for growth which investors should consider amid its market momentum.
Key Highlights
- Q2 revenue grew 22% from $11.4 million, driven by 28.1% Surgical Aesthetics growth
- Surgical Aesthetics revenue reached $12.4 million, with strong AYON platform performance
- This performance underscores Apyx Medical's potential in the evolving surgical aesthetics market, positioning it as a viable option for investors aiming to capitalize on trends in this field.
This performance underscores Apyx Medical's potential in the evolving surgical aesthetics market, positioning it as a viable option for investors aiming to capitalize on trends in this field.
Revenue Breakdown Shines
Apyx's successful commercial launch of the AYON Body Contouring System contributed significantly to this uptick, as it includes advanced technologies for body contouring procedures. The reliance on surgical aesthetics as the primary growth driver signals Apyx Medical's strategic pivot, which may influence future revenue streams.
Adjusted Figures Show Improvement
Gross profit also increased by 25% to $8.9 million, with gross margins improving to 63.9% from 62.3% in the previous year. The company’s financial performance, bolstered by effective cost management and an increasing focus on revenue-generating areas, presents a more favorable outlook for investors concerned about profitability metrics in growth-stage companies.
Future Guidance and Market Environment
Upcoming strategic initiatives, including further rollouts of the AYON system following FDA clearance for power liposuction, will be critical in maintaining market momentum.
Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...